Radiotherapy is living a second life in Renal Cell Carcinoma (RCC) patients, mainly due to the introduction of immunocheckpoint inhibitors, such as anti-Programmed-death (PD)-1, alone or in combination with anti-Cytotoxic T-Lymphocyte Antigen (CTLA)-4. Several trials are investigating the efficacy/safety of immunocheckpoint inhibitors in sequential or combined strategies with radiotherapy. Chimeric Antigen Receptor (CAR)-T cells therapy as a promising approach in cancer patients has opened the way to novel possibilities of integrating therapies. The identification of biomarkers of tumor response to these combinations represents a challenge in RCC, together with the research for the best partner for immunotherapy in metastatic patients. In this review we illustrated preclinical/clinical data on the integration of radiotherapy with immunocheckpoint inhibitors or CAR-T cells in RCC.
Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma / Santoni, Matteo; Heng, Daniel Yc; Aurilio, Gaetano; Iozzelli, Andrea; Servi, Lucilla; Fabiani, Andrea; Giannini, Massimo; Mazzucchelli, Roberta; Cimadamore, Alessia; Scarpelli, Marina; Zaghloul, Mohamed S; Battelli, Nicola; Montironi, Rodolfo. - In: CURRENT DRUG TARGETS. - ISSN 1389-4501. - 20:(2019). [10.2174/1389450120666191017113051]
Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma
Santoni, Matteo;Fabiani, Andrea;Mazzucchelli, Roberta;Cimadamore, Alessia;Scarpelli, Marina;Montironi, Rodolfo
2019-01-01
Abstract
Radiotherapy is living a second life in Renal Cell Carcinoma (RCC) patients, mainly due to the introduction of immunocheckpoint inhibitors, such as anti-Programmed-death (PD)-1, alone or in combination with anti-Cytotoxic T-Lymphocyte Antigen (CTLA)-4. Several trials are investigating the efficacy/safety of immunocheckpoint inhibitors in sequential or combined strategies with radiotherapy. Chimeric Antigen Receptor (CAR)-T cells therapy as a promising approach in cancer patients has opened the way to novel possibilities of integrating therapies. The identification of biomarkers of tumor response to these combinations represents a challenge in RCC, together with the research for the best partner for immunotherapy in metastatic patients. In this review we illustrated preclinical/clinical data on the integration of radiotherapy with immunocheckpoint inhibitors or CAR-T cells in RCC.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
